Grown Rogue International GAAP EPS of -$0.04, revenue of $11M

Grown Rogue International reported Q3 GAAP EPS of -$0.04 and revenue of $11M, up 29.4% year-over-year. The company had $16.6M in cash and equivalents as of September 30, 2026, up from $11.5M three months prior, according to a press release.

Original reporting
Published Nov 12, 2026, 10:37 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 12, 2026, 10:41 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$GRUSF
Bearish
high confidence
Mentioned
$GRUSF
Relevance
6/10
AlphAI data visualization · based on seekingalpha.com
Decision brief

The 30-second read

$GRUSFBearishMed
01

Why it matters

The earnings miss is the first public disclosure of the company's Q3 performance, offering traders a fresh data point.

02

Market read

New earnings data for a micro‑cap; likely limited to the stock itself.

03

What to watch

Cash balance rose to $16.6M, providing short‑term liquidity despite the loss.

Relevance 6/10Novelty 7/10Timing: today

Background

The article reproduces a press release from Grown Rogue International announcing its Q3 results.

Company-level read

Ticker impact

$GRUSFBearishHigh confidence
Context

Q3 GAAP EPS of -$0.04 and revenue of $11M were disclosed for the first time.

Expected impact

downward pressure as investors price in the loss

Evidence & confidence

Earnings miss (negative EPS) is a fresh, material data point for a thinly‑traded stock.

Market effects

Limited; reflects broader challenges for small‑cap biotech/tech firms reporting losses.

Minimal; company is US‑based but micro‑cap size limits broader impact.

Low

Counterpoint

Losses may be temporary; revenue growth could signal a turnaround if cash runway extends.

Key entities

  • Grown Rogue International Inc.

    Micro‑cap listed under the ticker GRUSF.

Related articles

$GRUSFLow

Grown Rogue Reports Third Quarter 2026 Results

Grown Rogue International Inc. (GRUSF) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Grown Rogue Reports Third Quarter 2026 Results Steady Execution Across Existing and New Markets; 2026 and 2027 Guidance and Growth Targets Maintained MEDFORD, Ore., Nov. 12, 2026 /CNW/ - Grown Rogue International Inc. ("Grown Rogue," "we," "us," "our," or the "Compan

$GRUSFMed

Grown Rogue Reports Second Quarter 2026 Results

Grown Rogue International Inc. (GRUSF) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Grown Rogue Reports Second Quarter 2026 Results Results and KPIs Highlight Continued Execution Against Growth Plans; 2026 and 2027 Guidance Increased MEDFORD, Ore., Aug. 4, 2026 /CNW/ - Grown Rogue International Inc. ("Grown Rogue," "we," "us," "our," or the "Company

$NMAXMed

Why Newsmax Stock Popped on Friday

Newsmax (NMAX) shares rose 31% after reporting Q3 revenue of $69M, up 52.5% YoY, and net income of $15.2M. The company cited strong audience engagement and growth in high-margin revenue streams. CEO Christopher Ruddy expects continued growth ahead of the presidential election.

$LUNRMed

What Is Driving Intuitive Machines Stock?

Intuitive Machines (LUNR) shares rose 7.0% on Nov 12, 2026, after reporting Q3 revenue of $269M, beating estimates. The company's loss of $0.10 per share met expectations, while gross margin improved to 26%. Free cash flow turned positive at $33M, a company record. Management raised full-year revenue guidance to $920M-$950M. The stock's performance contrasted with broader industry declines.

$RMIXMedAI 8/10

Suncrete (RMIX) Q3 2026 Earnings Call Transcript

Suncrete (RMIX) reported Q3 2026 revenue of $141M, up 45% QoQ and 163% YoY. Adjusted EBITDA rose 66% QoQ to $22.4M. The company lowered its full-year outlook due to residential construction weakness but remains confident in long-term demand. Acquisition integration is progressing, with North Texas showing margin improvement. Suncrete expects $200M-$250M revenue from 2026 acquisitions in 2027. The company has $206.5M in total liquidity.

$CLLSMed

Cellectis SA (CLLS) (Q3 2026) Earnings Call Highlights: Strategic Shift to Gene

Cellectis SA (CLLS) discussed its strategic shift to gene editing during its Q3 2026 earnings call. Management highlighted the selection of APOC3 over ANGPTL3 for triglyceride reduction, with plans to start Phase 1 dosing by end-2027. The company reported $149M in cash as of September 30, 2026, with a runway into H2 2028. Revenue decreased to $19.9M from $67.4M YoY, while R&D expenses increased to $108.8M from $69.1M, driven by the AstraZeneca collaboration.